학술논문
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group
Document Type
Original Paper
Author
Czyż, J; Hellmann, A; Dziadziuszko, R; Hansz, J; Goździk, J; Hołowiecki, J; Stella-Hołowiecka, B; Kachel, Ł; Knopińska-Posłuszny, W; Nagler, A; Meder, J; Walewski, J; Lampka, E; Sułek, K; Sawicki, W; Lange, A; Forgacz, K; Suchnicki, K; Pacuszko, T; Skotnicki, A; Mensah, P; Jurczak, W; Kuliczkowski, K; Wróbel, T; Mazur, G; Dmoszyńska, A; Wach, M; Robak, T; Warzocha, K
Source
Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 30(1):29-34
Subject
Language
English
ISSN
0268-3369
1476-5365
1476-5365
Abstract
We analysed the treatment outcome of primary refractory HD patients managed with high-dose chemotherapy and haematopoietic cell transplantation. Data of 65 adult patients who underwent HDC/ASCT in nine Polish centres for primary resistant Hodgkin's disease between June 1991 and July 2000 were collected retrospectively. Response rate to HDC/ASC: CR, 54%; PR, 20%; less than PR, 15%; early deaths, 11%. Actuarial 3-year OS and PFS were 55% and 36%, respectively. In multivariate analysis, lack of bulky lymph nodes and use of immunotherapy were favourable factors for both OS and PFS. IPF <3 at the time of transplantation was predictive for PFS. However, the prognostic impact of immunotherapy should be interpreted with caution since this group included more patients who achieved CR after HDC/ASCT. The results of HDC/ASCT are encouraging and confirm earlier findings. The role of immunotherapy should be further investigated in prospective trials.